Table III.
Comparison of patient characteristics, implicated drugs, and outcomes between patients treated with systemic and topical corticosteroids
| Baseline characteristics comorbidities | Systemic corticosteroids (n = 9) | Topical corticosteroids (n = 34) | P value |
|---|---|---|---|
| Age, mean ± SD, years | 57.6 (± 22.6) | 64.1 (± 14.4) | .157 |
| Male sex | 4 | 16 | .204 |
| Diabetes mellitus | 0 | 8 | .220 |
| Hypertension | 3 | 21 | .264 |
| Hyperlipidemia | 3 | 17 | .076 |
| Chronic kidney disease | 1 | 14 | .025 |
| Ischemic heart disease | 2 | 5 | .414 |
| Hepatobiliary | 1 | 0 | .524 |
| Dermatologic history | 1 | 3 | .445 |
| Malignancy | 0 | 4 | .380 |
| Implicated drugs | |||
| Penicillins | 1 | 12 | .076 |
| Cephalosporins | 0 | 5 | .344 |
| Quinolones | 2 | 2 | .500 |
| Macrolide | 1 | 0 | .524 |
| Clindamycin | 1 | 2 | .473 |
| Vancomycin | 2 | 2 | .500 |
| Other antibiotics | 0 | 2 | .445 |
| Calcium channel blockers | 0 | 2 | .445 |
| Antifungals | 0 | 2 | .445 |
| Analgesics | 1 | 2 | .473 |
| Contrast agent | 0 | 2 | .445 |
| Other medications | 0 | 2 | .445 |
| Systemic involvement | |||
| Elevated transaminases | 0 | 2 | .810 |
| Renal impairment | 3 | 1 | .026 |
| Outcomes | |||
| Median LOS in days (IQR) | 6.0 (5.0- 9.0) | 10.0 (6.2-31.5) | .035 |
| Mortality | 0 | 2 | .445 |
CI, Confidence interval, IQR, interquartile range; LOS, length of stay; RR, relative risk; SD, standard deviation.